Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease.
Progress in Neurobiology. 2015-09-01; 132: 96-168
DOI: 10.1016/j.pneurobio.2015.07.002
Read on PubMed
1. Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub
2015 Jul 21.
Pathophysiology of L-dopa-induced motor and non-motor complications in
Parkinson’s disease.
Bastide MF(1), Meissner WG(2), Picconi B(3), Fasano S(4), Fernagut PO(1), Feyder
M(5), Francardo V(6), Alcacer C(6), Ding Y(7), Brambilla R(4), Fisone G(5), Jon
Stoessl A(8), Bourdenx M(1), Engeln M(1), Navailles S(1), De Deurwaerdère P(1),
Ko WK(1), Simola N(9), Morelli M(9), Groc L(10), Rodriguez MC(11), Gurevich
EV(12), Quik M(13), Morari M(14), Mellone M(15), Gardoni F(15), Tronci E(16),
Guehl D(1), Tison F(2), Crossman AR(17), Kang UJ(6), Steece-Collier K(18), Fox
S(19), Carta M(16), Angela Cenci M(6), Bézard E(20).
Author information:
(1)Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France.
(2)Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France; Department of Neurology, University Hospital Bordeaux, France.
(3)Laboratory of Neurophysiology, Fondazione Santa Lucia, IRCCS, Rome, Italy.
(4)Division of Neuroscience, Institute of Experimental Neurology, San Raffaele
Scientific Institute, 20132 Milan, Italy.
(5)Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
(6)Basal Ganglia Pathophysiology Unit, Department of Experimental Medical
Science, Lund University, Lund, Sweden.
(7)Department of Neurology, Columbia University, New York, USA.
(8)Pacific Parkinson’s Research Centre and National Parkinson Foundation Centre
of Excellence, University of British Columbia, Vancouver, Canada.
(9)Department of Biomedical Sciences, Section of Neuropsychopharmacology,
Cagliari University, 09124 Cagliari, Italy.
(10)Univ. de Bordeaux, Institut Interdisciplinaire de neurosciences, UMR 5297,
33000 Bordeaux, France; CNRS, Institut Interdisciplinaire de neurosciences, UMR
5297, 33000 Bordeaux, France.
(11)Department of Neurology, Hospital Universitario Donostia and Neuroscience
Unit, Bio Donostia Research Institute, San Sebastian, Spain.
(12)Department of Pharmacology, Vanderbilt University Medical Center, Nashville,
TN 37232, USA.
(13)Center for Health Sciences, SRI International, CA 94025, USA.
(14)Department of Medical Sciences, Section of Pharmacology, University of
Ferrara, Ferrara, Italy.
(15)Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli
Studi di Milano, 20133 Milano, Italy.
(16)Department of Biomedical Sciences, Physiology Section, Cagliari University,
Cagliari, Italy.
(17)Motac Neuroscience Ltd, Manchester, UK.
(18)Michigan State University, College of Human Medicine, Department of
Translational Science and Molecular Medicine & The Udall Center of Excellence in
Parkinson’s Disease Research, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USA.
(19)Morton & Gloria Shulman Movement Disorders Center, Toronto Western Hospital,
Toronto, Ontario M4T 2S8, Canada.
(20)Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000
Bordeaux, France; Motac Neuroscience Ltd, Manchester, UK. Electronic address:
.
Involuntary movements, or dyskinesia, represent a debilitating complication of
levodopa (L-dopa) therapy for Parkinson’s disease (PD). L-dopa-induced dyskinesia
(LID) are ultimately experienced by the vast majority of patients. In addition,
psychiatric conditions often manifested as compulsive behaviours, are emerging as
a serious problem in the management of L-dopa therapy. The present review
attempts to provide an overview of our current understanding of dyskinesia and
other L-dopa-induced dysfunctions, a field that dramatically evolved in the past
twenty years. In view of the extensive literature on LID, there appeared a
critical need to re-frame the concepts, to highlight the most suitable models, to
review the central nervous system (CNS) circuitry that may be involved, and to
propose a pathophysiological framework was timely and necessary. An updated
review to clarify our understanding of LID and other L-dopa-related side effects
was therefore timely and necessary. This review should help in the development of
novel therapeutic strategies aimed at preventing the generation of dyskinetic
symptoms.
Copyright © 2015 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.pneurobio.2015.07.002
PMID: 26209473 [Indexed for MEDLINE]